Ligand Pharmaceuticals Incorporated
$ 255.54
0.38%
12 Jun - close price
- Market Cap 5,101,853,000 USD
- Current Price $ 255.54
- High / Low $ 259.03 / 250.49
- Stock P/E 33.23
- Book Value 49.79
- EPS 7.66
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.17 %
- 52 Week High 259.03
- 52 Week Low 110.00
About
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Analyst Target Price
$277.60
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 2.01 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.08 | $2.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LGND
2026-06-10 18:09:10
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, a non-binding advisory resolution on executive compensation, and an amendment and restatement of the Company’s 2002 Stock Incentive Plan. The approvals demonstrate strong investor support for the company's governance and compensation strategies.
2026-06-10 05:40:19
Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Additionally, 182 shares were withheld to cover tax liabilities associated with the RSU settlement, a non-market disposition.
2026-06-07 08:48:00
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit from a poor investment, as Reardon maintains significant direct and option holdings. The article highlights Ligand's strong one-year return and growing royalty revenue, advising investors to consider "The Motley Fool Stock Advisor" for top stock picks, though Ligand was not among them.
2026-06-03 03:39:33
Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and also impacted other heavily shorted stocks, caused significant outrage among retail investors and led to calls for Congressional hearings. The law firm is seeking to represent investors who suffered losses due to these limitations imposed by brokerage firms.
2026-05-26 11:39:36
Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an uplift in its 2026 revenue and EPS outlook. Despite being considered undervalued by analysts, current valuation may already reflect much of the anticipated growth, with key risks including regulatory uncertainty and potential exclusivity loss on some royalty streams.
2026-05-19 09:10:58
Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary of Ligand. The amendment aims to streamline the acquisition of XOMA Royalty.
